October 5-7, 2016
Boston Convention and Exhibition Center,
The most complete event to successfully blueprint cell, gene, and immunotherapies from proof of concept to commercialization
Join the unique event that brings together 300+ key industry and academic luminaries to collectively discuss strategies and share lessons learned resulting from their latest research data and case studies.
Accelerate Your Cell and Gene-Based products towards commercial success
This is the most comprehensive event that delivers the focused science and business content designed specifically for the cell therapy and regenerative medicine fields, while providing a pivotal gathering place for connecting industry, funding sources, government and academia.
Navigate the Pathway to Commercialization
Gain insights from 80+ global thought-leading speakers on how overcome today’s challenges involving scale-up, facility design, characterization, tech transfer, regulatory approval, investment, reimbursement and more. New in-depth content added includes:
- Gene Therapy
- Regulatory Concerns
Ensure a Successful Product-to-Market Launch
Evaluate leading technologies by meeting face-to-face with 25+ international CMOs, CROs and who can accelerate your product towards commercial success.
Meet the Right Partners to Grow Your Business
Connect with 300+ thought-leaders and service providers who can offer the strategic, technical and financial support to ensure a success cell-based product launch.
HEAR FROM WORLD-RENOWNED VISIONARIES TO BUILD SUCCESSFUL, SUSTAINABLE PRODUCTS
More than 80+ world-renowned thought leaders, experts, and visionaries in cell and gene therapy are assembling this October in Boston to share lessons learned, new data, and case studies to inspire and guide you towards a path of commercial success.
David DiGiusto, Ph.D.
Executive Director, Stem Cells and Cellular Therapeutics Operations; Founding Director, Stanford Laboratory for Cell and Gene Medicine; Senior Research Scientist, Division of Pediatric Stem Transplantation and Regenerative Medicine
Stanford Health Care/ Stanford School of Medicine
What Makes This Event Unique
No other event this Fall can match the coverage of the latest innovations to overcome obstacles in development, scale up, and commercialization of cell and gene-based products through the latest research data and case studies.
Six Focused Tracks
Keep your team up to date on the latest science, technologies and industry updates across the entire spectrum of cell therapy, gene therapy, and immuno-oncology product development:
- NEW! Regulatory Considerations
- NEW! Immuno-Oncology
- NEW! Gene Therapy Development & Production
- Cell Therapy Bioprocessing
- Tools & Technologies
Content For All Company Types
This year’s event presents a complete blueprint from bench to commercial scale that’s accessible for any sized company, including:
- Mid-Sized Gene and Cell Therapy Companies
- Biotech Start-Ups
- Virtual Companies
- Large Pharma and Biotechs
- Academic Institutions
Why People Come Back
"The go-to conference for everything related to Cell Therapy Bioprocessing and Commercialization.Great technology, a comprehensive program, and a wonderful exhibit hall. This conference is a great place to do business.” — Jon Rowley, Rooster Bio
“The only one of its kind.” — Mahendra Rao, NYSCF
“This is a great event to keep abreast of the manufacturing advancements for the rapidly evolving cell and gene therapy industry.” — Brian Hampson, PCT, A Caladrius Company
Progress Toward Commercial Scale and Efficiency in Cell Therapy Bioprocessing
Cell and gene therapy is an extremely promising and growing medical technology sector with 631 ongoing clinical trials at the end of 2015. It is applicable to oncology, cardiovascular disease, infectious diseases and other diseases. The merit of cell and gene therapy has been demonstrated by FDA approvals, however commercialisation can prove a high hurdle that can trip up even approved therapeutics such as Dendreon’s Provenge autologous cell therapy. There are however steps that can be taken to reduce the risk associated with commercialisation that companies with a cell and gene therapy portfolio should consider. This whitepaper discusses practical measures to improve the chances of commercial success:
- Characterization and Comparability Risk reduction through Quality by Design (QbD)
- Improving efficiency and reducing costs in development and production
- Novel analytical technologies and methodologies
- Ensuring successful process scale up and transfer
- Progress towards the industrialization of cell and gene therapies through modularisation
Present a Scientific Poster at Cell and Gene Therapy 2016
Highlight your company's latest research findings by presenting a scientific poster. The deadline to submit your poster is September 2, 2016.
Plan Your Visit
Boston is a bustling city, but you can cover the center on foot in just a couple of hours. With the history of the Freedom Trail, the modern attractions of the Institute of Contemporary Art and everything in between, Boston is worth exploring for a weekend. For information on the venue, official conference hotel details, transportation, and more click here.